title: Interferon-γ mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice.
abstract: OBJECTIVE
  Macrophage activation syndrome (MAS) is a devastating cytokine storm syndrome complicating many inflammatory diseases and characterized by fever, pancytopenia, and systemic inflammation. It is clinically similar to hemophagocytic lymphohistiocytosis (HLH), which is caused by viral infection of a host with impaired cellular cytotoxicity. Murine models of MAS and HLH illustrate that interferon-γ (IFNγ) is the driving stimulus for hemophagocytosis and immunopathology. This study was undertaken to investigate the inflammatory contributors to a murine model of Toll-like receptor 9 (TLR-9)-induced fulminant MAS.
  
  
  METHODS
  Wild-type, transgenic, and cytokine-inhibited mice were treated with an IL-10 receptor blocking antibody and a TLR-9 agonist, and parameters of MAS were evaluated.
  
  
  RESULTS
  Fulminant MAS was characterized by dramatic elevations in IFNγ, IL-12, and IL-6 levels. Increased serum IFNγ levels were associated with enhanced IFNγ production within some hepatic cell populations but also with decreased numbers of IFNγ-positive cells. Surprisingly, IFNγ-knockout mice developed immunopathology and hemophagocytosis comparable to that seen in wild-type mice. However, IFNγ-knockout mice did not become anemic and had greater numbers of splenic erythroid precursors. IL-12 neutralization phenocopied disease in IFNγ-knockout mice. Interestingly, type I IFNs contributed to the severity of hypercytokinemia and weight loss, but their absence did not otherwise affect MAS manifestations.
  
  
  CONCLUSIONS
  These data demonstrate that both fulminant MAS and hemophagocytosis can arise independently of IFNγ, IL-12, or type I IFNs. They also suggest that IFNγ-mediated dyserythropoiesis, not hemophagocytosis, is the dominant cause of anemia in fulminant TLR-9-induced MAS. Thus, our data establish a novel mechanism for the acute anemia of inflammation, but suggest that a variety of triggers can result in hemophagocytic disease.
authors.affiliation: The Children's Hospital of Philadelphia, Philadelphia, PA, USA. cannas@email.chop.edu
authors.forename: Scott W
authors.initials: SW
authors.lastname: Canna
authors.forename: Julia
authors.initials: J
authors.lastname: Wrobel
authors.forename: Niansheng
authors.initials: N
authors.lastname: Chu
authors.forename: Portia A
authors.initials: PA
authors.lastname: Kreiger
authors.forename: Michele
authors.initials: M
authors.lastname: Paessler
authors.forename: Edward M
authors.initials: EM
authors.lastname: Behrens
mesh_terms: D000740:Anemia / Q000209:etiology / Q000503:physiopathology*; D000818:Animals; D004195:Disease Models, Animal; D004920:Erythropoiesis / Q000502:physiology*; D018836:Inflammation Mediators / Q000276:immunology; D007370:Interferon Type I / Q000502:physiology; D007371:Interferon-gamma / Q000235:genetics / Q000502:physiology*; D018664:Interleukin-12 / Q000502:physiology; D051359:Lymphohistiocytosis, Hemophagocytic / Q000150:complications / Q000276:immunology / Q000503:physiopathology*; D055501:Macrophage Activation Syndrome / Q000150:complications / Q000276:immunology / Q000503:physiopathology*; D051379:Mice; D018345:Mice, Knockout; D015398:Signal Transduction / Q000502:physiology; D051217:Toll-Like Receptor 9 / Q000819:agonists
chemical_list: D018836:Inflammation Mediators; D007370:Interferon Type I; D051217:Toll-Like Receptor 9; D018664:Interleukin-12; D007371:Interferon-gamma
references.citation: Arthritis Rheum. 2008 Sep;58(9):2892-6
references.pmid: 18759271
references.citation: Arthritis Rheum. 1989 Jul;32(7):914-8
references.pmid: 2751723
references.citation: Immunol Rev. 2008 Dec;226:205-18
references.pmid: 19161426
references.citation: Blood. 2011 Apr 14;117(15):e151-60
references.pmid: 21325597
references.citation: J Exp Med. 2003 Oct 6;198(7):1069-76
references.pmid: 14530376
references.citation: Vaccine. 2006 Jun 12;24(24):5110-8
references.pmid: 16725231
references.citation: J Clin Invest. 2011 Jun;121(6):2264-77
references.pmid: 21576823
references.citation: Arthritis Rheum. 2012 May;64(5):1680-8
references.pmid: 22108837
references.citation: Blood. 1994 Feb 15;83(4):911-5
references.pmid: 8111063
references.citation: Histopathology. 1998 Apr;32(4):310-6
references.pmid: 9602326
references.citation: Eur J Haematol. 2006 Nov;77(5):432-6
references.pmid: 17044836
references.citation: EMBO Mol Med. 2009 May;1(2):112-24
references.pmid: 20049711
references.citation: Rheumatology (Oxford). 2010 Mar;49(3):441-9
references.pmid: 20019066
references.citation: J Exp Med. 2007 Apr 16;204(4):853-63
references.pmid: 17420270
references.citation: J Exp Med. 2011 Jun 6;208(6):1203-14
references.pmid: 21624938
references.citation: J Immunol. 2003 Jul 1;171(1):285-90
references.pmid: 12817009
references.citation: Arthritis Rheum. 2012 Nov;64(11):3799-808
references.pmid: 22740319
references.citation: J Clin Pathol. 2001 Dec;54(12):961-3
references.pmid: 11729218
references.citation: Clin Exp Immunol. 2003 Sep;133(3):448-53
references.pmid: 12930373
references.citation: PLoS One. 2010 Feb 26;5(2):e9441
references.pmid: 20195482
references.citation: J Rheumatol. 2010 May;37(5):967-73
references.pmid: 20231207
references.citation: Cytokine. 2012 Oct;60(1):226-32
references.pmid: 22682876
references.citation: J Rheumatol. 2007 May;34(5):1133-8
references.pmid: 17343315
references.citation: Blood. 2010 Oct 7;116(14):2476-83
references.pmid: 20570861
references.citation: Curr Opin Rheumatol. 2012 Jan;24(1):113-8
references.pmid: 22089101
references.citation: J Virol. 2010 Sep;84(18):9452-62
references.pmid: 20592086
references.citation: Blood. 2011 May 26;117(21):5663-73
references.pmid: 21467545
references.citation: J Immunol. 1984 Aug;133(2):769-74
references.pmid: 6203978
references.citation: Curr Opin Rheumatol. 2010 Sep;22(5):561-6
references.pmid: 20517154
references.citation: Annu Rev Immunol. 2001;19:683-765
references.pmid: 11244051
references.citation: Blood. 2011 Jun 16;117(24):6582-8
references.pmid: 21551232
references.citation: Pediatr Crit Care Med. 2009 May;10(3):387-92
references.pmid: 19325510
references.citation: Blood. 2004 Aug 1;104(3):735-43
references.pmid: 15069016
references.citation: Science. 2011 Nov 11;334(6057):799-802
references.pmid: 22076376
references.citation: Rheumatology (Oxford). 2010 Sep;49(9):1645-53
references.pmid: 20472718
references.citation: Immunol Rev. 2010 May;235(1):10-23
references.pmid: 20536552
references.citation: Blood. 2011 Jul 21;118(3):618-26
references.pmid: 21606480
references.citation: J Pediatr. 2003 Mar;142(3):292-6
references.pmid: 12640378
references.citation: Hematol Oncol Clin North Am. 1998 Apr;12(2):435-44
references.pmid: 9561911